

<b>Appendix Table:</b> Predictors of opioid agonist therapy in outpatient admissions with primary opioid use disorder in Treatment Episode Data Set-Admissions, 2010-2016 (states with information on insurance status).								
	<b>Model 1</b>		<b>Model 2</b>		<b>Model 3</b>		<b>Model 4</b>	
	<b>aOR</b>	<b>95% CI</b>	<b>aOR</b>	<b>95% CI</b>	<b>aOR</b>	<b>95% CI</b>	<b>aOR</b>	<b>95% CI</b>
Period								
2010-2013	Ref		Ref		Ref		Ref	
2014-2016	1.16	1.15-1.17	1.16	1.15-1.17	0.93	0.90-0.96	0.96	0.93-0.99
Expansion state <sup>a</sup>	-- <sup>b</sup>	-- <sup>b</sup>	1.66	0.70-3.95	1.49	0.62-3.55	1.54	0.64-3.69
Period*Expansion state	-- <sup>b</sup>	-- <sup>b</sup>	-- <sup>b</sup>	-- <sup>b</sup>	1.28	1.24-1.32	1.03	0.99-1.06
Medicaid insurance	-- <sup>b</sup>	-- <sup>b</sup>	-- <sup>b</sup>	-- <sup>b</sup>	-- <sup>b</sup>	-- <sup>b</sup>	1.79	1.77-1.81
Age								
<25	Ref		Ref		Ref		Ref	
25-29	1.63	1.60-1.65	1.63	1.60-1.65	1.63	1.60-1.65	1.58	1.56-1.61
30-39	2.16	2.13-2.19	2.16	2.13-2.19	2.16	2.13-2.19	2.09	2.06-2.12
40-50	2.73	2.68-2.78	2.73	2.68-2.78	2.73	2.68-2.78	2.68	2.63-2.73
50+	4.14	4.06-4.22	4.14	4.06-4.22	4.14	4.06-4.22	3.98	3.91-4.06
Female sex	1.43	1.42-1.44	1.43	1.42-1.44	1.43	1.42-1.44	1.31	1.30-1.32
Race/ethnicity								
Non-Hispanic white	Ref		Ref		Ref		Ref	
Non-Hispanic black	0.83	0.82-0.85	0.83	0.82-0.85	0.83	0.82-0.85	0.84	0.82-0.85
Hispanic	1.15	1.13-1.18	1.15	1.13-1.18	1.15	1.13-1.18	1.04	1.02-1.06
Other	0.95	0.91-0.98	0.95	0.91-0.98	0.95	0.91-0.98	0.81	0.78-0.84
Homeless	0.61	0.60-0.62	0.61	0.60-0.62	0.61	0.60-0.62	0.59	0.57-0.60
Any prior treatment	0.89	0.88-0.90	0.89	0.88-0.90	0.89	0.88-0.91	0.88	0.87-0.89
IV drug use <sup>c</sup>	1.10	1.09-1.11	1.10	1.09-1.11	1.10	1.09-1.11	1.10	1.08-1.11
Heroin use <sup>c</sup>	1.95	1.91-1.98	1.95	1.91-1.98	1.96	1.92-1.99	2.00	1.96-2.03
Other opioid use <sup>c</sup>	1.12	1.11-1.14	1.12	1.11-1.14	1.13	1.11-1.14	1.12	1.11-1.14
Data from Treatment Episode Data Set-Admissions (TEDS-A).								
Abbreviations: aOR stands for adjusted odds ratio, CI for confidence interval, IV drug use for intravenous drug use.								
<sup>a</sup> Expansion states with insurance information included 20 states (Arkansas, Colorado, Delaware, Hawaii, Illinois, Indiana, Iowa, Kentucky, Maryland, Massachusetts, Nevada, New Hampshire, New Jersey, New Mexico, Ohio, Oregon, Pennsylvania, Rhode Island, Vermont, and West Virginia); non-expansion states included 11 states (Alabama, Alaska, Idaho, Louisiana, Maine, Mississippi, Missouri, Nebraska, South Dakota, Texas, Utah). District of Columbia was categorized along with expansion states and Puerto Rico with non-expansion states.								
<sup>b</sup> Not in the model.								
<sup>c</sup> Based on type of substance and route of administration for primary, secondary or tertiary substances.								